Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Breast Neoplasms 2Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 498Bevacizumab 476Oxaliplatin 450Leucovorin 442Irinotecan 408Cetuximab 318Capecitabine 317pembrolizumab 142Folfox protocol 128Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 82IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 47Standard of Care 45Neoadjuvant Therapy 45Magnetic Resonance Spectroscopy 44Biopsy 44Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 39Cyclophosphamide 39Surveys and Questionnaires 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × C188-9 compound × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡